Diamonds and Dogs


Synageva BioPharma Corp. (GEVA)

Synageva is doubling its investors' money today, up 112.84% to $204.00. The biopharmaceutical company saw its shares explode after news that Alexion Pharma would buy Synageva for $8.4 billion. Alexion is interested in Synageva's pipeline which includes; Kanuma, a potential treatment that's currently being reviewed by the Food and Drug Administration, which is expected to decide by September whether to approve it. Kanuma treats lysosomal acid lipase deficiency, a disease that causes the buildup of fatty material in the liver and blood vessels and can cause serious health problems or death. Shares of Synageva rallied over $108.00 today to a new 52-week high of $215.74.

Ardelyx Inc. (ARDX)

Ardelyx Inc. is sliding lower today, down 24.56% to $8.23. The metabolic and gastrointestinal company saw its shares tank after releasing results from its Phase 2a trial. The 154-patient Phase 2a clinical trial evaluating tenapanor in Stage 3 chronic kidney disease patients with type 2 diabetes mellitus and albuminuria did not meet the primary endpoint of decreasing the urinary albumin-creatinine ratio in tenapanor-treated patients compared to patients receiving placebo.Shares of Ardelyx fell over $2.75 today to a new 52-week low of $7.95.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.